We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Circulating Small Extracellular Vesicles Provide Liquid Biopsy Biomarkers for Glioblastoma Diagnosis

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Image: Preparation protocol: sEVs from GB patients and healthy volunteers’ blood samples were isolated by ultracentrifugation. The proteomic content of the sEVs were determined using mass spectrometry (Photo courtesy of Biomedicines)
Image: Preparation protocol: sEVs from GB patients and healthy volunteers’ blood samples were isolated by ultracentrifugation. The proteomic content of the sEVs were determined using mass spectrometry (Photo courtesy of Biomedicines)
A recently published paper described the development of a non-invasive liquid biopsy approach for the identification of biomarkers that could significantly improve glioblastoma (GB) diagnosis and, consequently, patients’ prognosis and quality of life.

Glioblastoma is the most common primary tumor of the central nervous system and is almost always fatal. The aggressive invasion of glioblastoma cells into the surrounding normal brain makes complete surgical removal impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Currently, serial brain imaging is used for detecting tumor progression. However, this modality is challenging, as it is sometimes difficult to determine true progression from pseudo-progression.

Small extracellular vesicles (sEVs) produced by both GBM and stromal cells are central in the inter-cellular communication that is taking place within the tumor microenvironment. EVs, which include exosomes, microvesicles, and apoptotic bodies, are cell-derived lipid-bilayer-enclosed structures, with sizes ranging from 30 to 5,000 nanometers. In the past decade, EVs have emerged as important mediators of cell communication because they serve as vehicles for the intercellular transmission of biological signals (proteins or nucleic acids) capable of altering cell function and physiology.

EV-based liquid biopsies have been suggested as a promising tool for GB diagnosis and follow up. To identify GB specific proteins, investigators at the University Sussex (United Kingdom) isolated sEVs from plasma samples of GB patients as well as healthy volunteers using differential ultracentrifugation, and their content was characterized through mass spectrometry.

Results revealed the presence in the sEVs of an inflammatory biomarker signature comprising members of complement and regulators of inflammation and coagulation including von Willebrand factor (VWF), IgGFc-binding protein (FCGBP), Complement component 3 (C3), protein S (PROS1), and Alpha-1 antitrypsin (SERPINA1).

Senior author Dr. Georgios Giamas, professor of cancer cell signaling at the University of Sussex, said, "Currently, glioblastoma detection relies on the display of symptoms, magnetic resonance imaging, and invasive tissue biopsies—all of which can delay the identification of the rapidly growing malignant mass. A growing body of research is looking into the possibility of developing liquid biopsies which would afford timely and non-invasive assessment of the disease in patients, starting from just a small sample of blood. Our study, which effectively does this in a small patient group, is a major step forward in the development of an accurate, non-invasive, and time-saving diagnosis method. If we can show that the biomarker signatures of extracellular vesicles obtained from blood samples change/disappear then this could be a huge breakthrough for monitoring the success of treatments too."

The paper was published in the January 7, 2022, online edition of the journal Biomedicines.

Related Links:
University Sussex

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.